TORONTO, CANADA — (October 22, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has established a strategic advisory board to support its business development activities.
“We are very pleased to welcome four superb pharma executives to our team of advisors who share our view of Antibe’s science and potential,” remarked Dan Legault, Antibe’s CEO. “They’re industry veterans who know how to identify, grow and monetize pharmaceutical assets. They have an impressive track record of executing transformational transactions that will be invaluable as we engage global pharmaceutical firms for potential partnerships in the major markets.”
The advisory board consists of recognized industry leaders: Angus Russell, Dominique Monnet, Andrew Powell and Rami Batal.
Angus Russell was the CEO of Shire from 2008 until his retirement in 2013 where he transformed the company into a global leader focused on rare diseases. During his tenure, he successfully concluded a series of late-stage deals that included several promising therapies addressing both acute and critical rare diseases. Earlier in his career, Angus held roles of increasing responsibility at ICI, Zeneca, AstraZeneca and Shire. He currently serves as the Chairman of Mallinckrodt, a leading global specialty pharmaceutical company. Angus is also Chairman of Revance Therapeutics, a biotechnology company focused on dermatology and aesthetic medicines, and an independent director at TherapeuticsMD, an innovative women’s healthcare company.
Dominique Monnet has more than 35 years of leadership experience in the biopharma industry, in the U.S. and internationally. He served as Senior Vice President and Chief Marketing Officer of Alexion in 2014 to 2015. From 2002 to 2013, Dominique was a senior business executive at Amgen. Of particular relevance to Antibe, he was responsible for accelerating the growth of Amgen’s Inflammation Business Unit and its Enbrel® franchise in the United States. He also led the creation of Amgen’s successful international franchises in oncology and nephrology. He is currently President of PDL BioPharma, which manages a portfolio of companies, products and royalty agreements in the healthcare sector.
Andrew Powell is highly regarded for his ability to strategically position life science assets and companies for a monetization event. He played an instrumental role in the completion of a series of prominent deals, including: the sale of Medivation to Pfizer for US$14 billion; the sale of InterMune to Roche for US$8.3 billion; and the sale of ImClone to Eli Lilly for US$6.5 billion. Earlier in his career, Andrew negotiated and managed international joint ventures for Baxter International. He currently serves as a director at Aclaris Therapeutics, a biopharmaceutical company focused on dermatology, and as a director at Landec, a leading innovator of diversified health and wellness solutions.
Rami Batal was most recently a senior business development officer for Purdue Canada and brings to Antibe vast experience in the pain markets. At Purdue Canada, Rami led the expansion of the product portfolio into other CNS areas, including other pain platforms, as well as cancer supportive care. Over his career, Rami has worked with Big Pharma, biotech startups and government and academic interests in North America and Europe, as well as in emerging markets in Asia and the Middle East. Currently, Rami is Vice President, Medical Research of Canopy Growth, where he is responsible for setting up and managing clinical development programs in CNS disorders.
About Antibe Therapeutics Inc.Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a gastrointestinal-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking InformationThis news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact InformationAntibe Therapeutics Inc.
Chief Executive Officer
Tel: +1 416-473-4095